News & Milestones

Shilpa Biologicals Pvt. Ltd., a fully integrated biologics company and subsidiary of Shilpa Medicare, has entered into a strategic licensing agreement with SteinCares, a leading specialty healthcare firm focused on Latin America.

Under the agreement, SteinCares will hold exclusive rights to register, commercialise, and distribute a selected biosimilar product across the Latin American region, leveraging its strong regulatory and market access capabilities. Shilpa Biologicals will complete the product development and provide long-term commercial manufacturing from its state-of-the-art biologics facility in Dharwad, India.

This partnership combines Shilpa’s biologics development and manufacturing expertise with SteinCares’ regional commercial network, aiming to accelerate patient access to high-quality, affordable biologic therapies in emerging markets.

Shilpa Biologicals, Dharwad, has entered into a strategic Memorandum of Understanding (MoU) with the Indian Institute of Technology Dharwad (IIT Dharwad) on 21 January 2026, aimed at fostering a long-term collaborative framework between industry and academia.

The partnership brings together Shilpa Biologicals’ industrial expertise and IIT Dharwad’s research capabilities in biosciences, biotechnology, chemical engineering, and allied disciplines. It is designed to promote joint research and development, facilitate technology translation, support innovation-driven solutions, and address real-world industrial challenges.

Under the collaboration, both organizations will work closely on joint research projects, student internships, faculty-industry interactions, skill development programs, and supervision of research scholars. The MoU also seeks to advance innovation in biopharmaceutical processes, sustainable biomanufacturing, and advanced biotechnological solutions — contributing to national priorities in healthcare and technology-led growth.

This partnership is expected to create meaningful opportunities for students, researchers, and industry professionals, while reinforcing the commitment of Shilpa Biologicals to academic engagement and innovation excellence.

We wish to inform you that, in accordance with the latest directives from the GST Council and the National Pharmaceutical Pricing Authority (NPPA), significant changes to the Goods and Services Tax (GST) and Drugs (Prices Control) Order (DPCO) will come into effect starting 22nd September 2025. In line of these guideline , Shilpa Medicare Ltd is publishing the Product Information like Brand Name, generic Name, PTS, PTR ,Old MRP , Old GST Rate & Revised GST Rate along with Revised MRP effective from 22nd Sep 2025 to ease the Business Operation of Our All Associates along with Awareness on Pricing & tax Structure . It is mandatory to pass the Benefit of Reduction of GST rate to ultimate customer. Attached is the Guideline & Product Details .

Shilpa Medicare Ltd has launched Sunitinib Capsules 12.5 mg, 25 mg & 50 mg in Indian market under brand name "SUNISHIL". Sunitinib Capsules are indicated for the treatment of Gastrointestinal stromal tumour (GIST), Metastatic renal cell carcinoma (MRCC) & Pancreatic neuroendocrine tumours (pNET). SUNISHIL is a therapeutic equivalent of the brand leader SUTENT.

Know More View PDF

New bioconjugation services to complete the CDMO’s end-to-end capabilities across payload, linker, and MAb

Shilpa to undertake both development and commercial supply for mAbTree’s novel checkpoint inhibitor

Integrated CDMO has capabilities spanning small and large molecules as well as peptides with ‘off-the-shelf’ commercially ready formulations for license

View PDF

We are delighted to announce that Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), has received the Marketing Authorization Permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of Adalimumab higher concentration formulation (100mg/mL) in India. This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume.

Shilpa Biologicals' extensive research and development efforts have resulted in the successful development of a high concentration biosimilar that matches the safety, purity, and potency profiles of the reference product. This achievement underscores the company's commitment to development of biosimilars and its mission to improve global healthcare outcomes. SBPL has been working on development of biosimilars catering to different therapeutic areas such as Immunology, Oncology, Ophthalmology, among which, Adalimumab is the first Biosimilar from Shilpa Biologicals Private Limited.